Home » Stocks » Recro Pharma

Recro Pharma, Inc. (REPH)

Stock Price: $1.96 USD -0.02 (-1.01%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $1.97 +0.01 (0.51%) Oct 23, 6:07 PM

Stock Price Chart

Key Info

Market Cap 46.34M
Revenue (ttm) 80.20M
Net Income (ttm) -27.52M
Shares Out 23.64M
EPS (ttm) -1.19
PE Ratio n/a
Forward PE 18.25
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $1.96
Previous Close $1.98
Change ($) -0.02
Change (%) -1.01%
Day's Open 1.99
Day's Range 1.94 - 2.01
Day's Volume 96,131
52-Week Range 1.91 - 19.21

More Stats

Market Cap 46.34M
Enterprise Value 140.10M
Earnings Date (est) Nov 5, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.64M
Float 20.03M
EPS (basic) -1.19
EPS (diluted) -1.19
FCF / Share 0.18
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 8.92%
Payout Ratio n/a
Shares Short 574,925
Short Ratio 1.88
Short % of Float 2.87%
Beta 0.59
PE Ratio n/a
Forward PE 18.25
P/FCF Ratio 11.21
PS Ratio 0.58
PB Ratio n/a
Revenue 80.20M
Operating Income 36.53M
Net Income -27.52M
Free Cash Flow 4.13M
Net Cash -93.77M
Net Cash / Share -3.97
Gross Margin 60.15%
Operating Margin 45.55%
Profit Margin -34.30%
FCF Margin 5.15%
ROA 3.56%
ROE n/a
ROIC -3.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.50*
(282.65% upside)
Low
5.00
Current: $1.96
High
10.00
Target: 7.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue99.2277.3571.8369.3451.95---
Revenue Growth28.28%7.67%3.6%33.46%----
Gross Profit48.2434.1933.6432.1923.90---
Operating Income25.7512.7712.27-16.42-3.28-11.87-1.09-0.88
Net Income-18.63-79.72-50.08-30.213.03-16.13-1.96-1.54
Shares Outstanding22.4120.4719.0710.728.496.240.160.16
Earnings Per Share-0.79-3.90-2.63-2.820.21-2.79-15.41-12.53
Dividend Per Share1.80-------
Operating Cash Flow-25.50-43.12-17.04-3.208.46-10.87-0.82-1.22
Capital Expenditures-8.34-7.20-5.40-3.77-2.41---
Free Cash Flow-33.84-50.31-22.45-6.976.05-10.87-0.82-1.22
Cash & Equivalents19.1538.5164.4864.4819.7819.680.010.05
Total Debt11064.2453.6024.3929.76-11.9110.16
Net Cash / Debt-91.17-25.7310.8840.10-9.9819.68-11.89-10.11
Assets11015518618313920.370.850.15
Liabilities11717515711198.351.4512.9310.28
Book Value-6.71-19.5028.8571.6140.3518.93-17.96-15.56
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Recro Pharma, Inc.
Country United States
Employees 213
CEO Gerri A. Henwood

Stock Information

Ticker Symbol REPH
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: REPH
IPO Date March 7, 2014

Description

Recro Pharma a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.